• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Aktis Oncology (AKTS) Valuation Check After Recent Share Price Weakness And Lower Price To Book Ratio

    Simply Wall St·05/22/2026 07:38:08
    Listen to the news

    Aktis Oncology stock: key recent moves

    Aktis Oncology (AKTS) has drawn attention after recent trading left the stock at a last close of $19.12, with short term returns mixed and year to date performance currently showing a double digit decline.

    See our latest analysis for Aktis Oncology.

    Recent trading shows momentum fading, with a 7 day share price return of 1.95% lower and a 30 day share price return of 6.73% lower, while the year to date share price return is 14.64% lower from the current US$19.12 level.

    If Aktis Oncology has caught your eye, it can help to compare its profile with other healthcare and radiopharmaceutical exposures using our screener for 33 healthcare AI stocks

    With Aktis Oncology still loss making and trading below the average analyst price target of US$32.25, the key question is whether the current US$19.12 level reflects a discount or if markets are already pricing in future growth.

    Price to book of 2.1x: is it justified?

    Aktis Oncology currently trades on a P/B of 2.1x, which screens as cheaper than both its direct peer group at 3.9x and the broader US biotechs average at 2.4x.

    The P/B ratio compares the company’s market value to its book value. For a clinical stage biotech that is still loss making, this measure often reflects what the market is willing to pay for its asset base, pipeline and cash relative to its accounting equity. A lower P/B than peers can indicate that investors are more cautious about the company’s prospects or that the stock may be trading at a discount to similar businesses.

    Relative to both its immediate peers and the wider industry, Aktis Oncology’s 2.1x P/B sits meaningfully below the averages. This suggests the stock is currently priced more conservatively than many comparable biotechs. With no fair ratio available, there is no additional regression based anchor for where this multiple could trend over time, so comparisons rest entirely on peer and sector levels for now.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price to book of 2.1x (UNDERVALUED)

    However, this more conservative P/B sits alongside risks such as ongoing losses of US$67.071m and dependence on early stage clinical programs that may not progress as planned.

    Find out about the key risks to this Aktis Oncology narrative.

    Next Steps

    Mixed signals in the story so far? Take a closer look at the numbers yourself, weigh the concerns and potential upside, and review the 2 key rewards and 2 important warning signs

    Looking for more investment ideas?

    If Aktis Oncology is on your watchlist, do not stop there. Broadening your search across different types of opportunities can help you build a more resilient portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.